Related Experiment Video
Updated: Jul 20, 2026
09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Apolipoprotein E gene polymorphism and previous alcohol withdrawal seizures
Julia Wilhelm1, Nicolas von Ahsen, Thomas Hillemacher
1Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Schwabachanlage 6, D-91054 Erlangen, Germany. julia.wilhelm@psych.imed.uni-erlangen.de
Journal of Psychiatric Research
|September 9, 2006
Summary
The apolipoprotein E3 (ApoE3) gene variant is linked to an increased risk of alcohol withdrawal seizures. Conversely, the ApoE2 variant showed a protective association against these seizures in alcohol-dependent patients.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Alcohol dependence is a significant public health issue.
- Alcohol withdrawal seizures are a serious complication of alcohol cessation.
- The role of genetic factors, such as apolipoprotein E (ApoE) gene polymorphism, in alcohol withdrawal seizures requires further investigation.
Purpose of the Study:
- To explore the association between apolipoprotein E (ApoE) gene polymorphism and a history of alcohol withdrawal seizures.
- To determine if specific ApoE alleles influence the risk or protection against alcohol withdrawal seizures.
Main Methods:
- A case-control study involving 194 patients with alcohol dependence.
- Patients were categorized based on a history of alcohol withdrawal seizures (SZ+) versus no history (SZ-).
- Apolipoprotein E (ApoE) genotypes were determined using polymerase chain reaction (PCR) and analyzed for allele frequencies.
Main Results:
- A significant positive association was observed between the ApoE3 allele and a history of alcohol withdrawal seizures (Fisher's exact test: p=0.006).
- A significant negative association (protective effect) was found for the ApoE2 allele (Fisher's exact test: p=0.029).
- No significant association was found between the ApoE4 allele and alcohol withdrawal seizures.
Conclusions:
- The findings suggest that the apolipoprotein E3 gene variant may be associated with an elevated risk of alcohol withdrawal seizures.
- The apolipoprotein E2 gene variant may confer a protective effect against alcohol withdrawal seizures.
- Further research is needed to validate these preliminary findings in larger cohorts.
More Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...